circadian rhythm comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-03-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule ligand; not a hormone or peptide |
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| CAS Registry Number | 1379686-30-2 | Unique chemical identifier |
| Common synonyms | SR9009; stenabolic | Stenabolic is informal and not an official name |
| Reported targets | REV-ERBα and REV-ERBβ | Nuclear receptors linked to circadian and metabolic regulation |
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
=== Psychotropic effects === Bromantane is described primarily as a mild stimulant and anxiolytic. It is also said to possess anti-asthenic properties. Bromantane is reported to improve physical and mental performance, hence it could be considered a performance-enhancing drug. Bromantane has been found to lower the levels of pro-inflammatory cytokines IL-6, IL-17 and IL-4 and to normalize behavior in animal models of depression, and may possess clinical efficacy as an antidepressant. It has also been found to increase sexual receptivity and proceptivity in rats of both sexes, which was attributed to its dopaminergic actions. It has been proposed that bromantane may suppress prolactin levels by virtue of its dopaminergic properties as well. Bromantane has been found to "agonize" amphetamine-induced stereotypies in vivo, suggesting that it might potentiate certain effects of other stimulants. The stimulant effects of bromantane onset gradually within 1.5–2 hours and last for 8–12 hours when taken orally.
=== Mechanism of toxicity in humans === After FIAU is converted to FIAU-TP, it is not only available to viral polymerase, in humans it can also be taken up into mitochondria and used by mitochondrial DNA polymerase γ (POLG). When FIAU is incorporated into mitochondrial DNA (mtDNA), it disrupts mtDNA replication, which leads to mtDNA depletion. With less mtDNA, cells can make fewer proteins for the electron transport chain, so oxidative phosphorylation fails. The consequences are lactic acidosis (shift to anaerobic metabolism) and microvascular steatosis (impaired fatty-acid oxidation), especially in the liver
Through US DOE ARPA-E's Nuclear Energy Waste Transmutation Optimized Now, or NEWTON program, the DOE aims to explore economically viable transmutation at a scale for transmutation of commercially used US nuclear fuel stockpile within 30 years mainly focusing on particle accelerator technology. The program expects to process used nuclear fuel to reduce the time it requires to reach radiotoxicity of natural uranium ore, from 100,000 years of cooling to 300 years. High energy proton beams are used in production of neutron beams through collision with heavy element target, like lead or bismuth, in a process called spallation. Reducing the size and cost of such setup is a major area of focus for practical viability of the process. 2018 Nobel Prize for Physics-winner Gérard Mourou has proposed using chirped pulse amplification to generate high-energy and low-duration laser pulses either to accelerate deuterons into a tritium target causing fusion events yielding fast neutrons, or accelerating protons for neutron spallation, with either method intended for transmutation of nuclear waste.
In Swansea's maritime quarter are the Dylan Thomas Theatre, home of the Swansea Little Theatre of which Thomas was once a member, and the former Guildhall, built in 1825 and now occupied by the Dylan Thomas Centre, a literature centre, where exhibitions and lectures are held and setting for the annual Dylan Thomas Festival.
Sources: en.wikipedia.org
==== Ethanol distillation ==== Graphene oxide membranes allow water vapor to pass through, but are impermeable to other liquids and gases. This phenomenon has been used for further distilling of vodka to higher alcohol concentrations, in a room-temperature laboratory, without the application of heat or vacuum as used in traditional distillation methods. Further development and commercialization of such membranes could revolutionize the economics of biofuel production and the alcoholic beverage industry.
== Philosophy == Adorno's work sets out from a central insight he shares with all early 20th-century avant-garde art: the recognition of what is primitive in ourselves and the world itself. Neither Picasso's fascination with African sculpture nor Mondrian's reduction of painting to its most elementary component—the line—is comprehensible outside this concern with primitivism, which Adorno shared with the century's most radical art. At that time, the Western world, beset by world wars, colonialist consolidation, and accelerating commodification, sank into the very barbarism civilization had prided itself in overcoming. According to Adorno, society's self-preservation had become indistinguishable from the socially sanctioned self-sacrifice of "primitive" people, the primitive aspects of the ego, and those primitive, mimetic desires found in imitation and sympathy. Adorno's theory proceeds from an understanding of this primitive quality of reality that seeks to counteract whatever aims either to repress this primitive aspect or to further those systems of domination set in place by this return to barbarism. From this perspective, Adorno's writings on politics, philosophy, music, and literature are a lifelong critique of the ways in which each tries to justify self-mutilation as the necessary price of self-preservation.
== Clinical significance == In addition to their roles in cancer development and chemotherapeutic drug resistance, GSTs are implicated in a variety of diseases by virtue of their involvement with GSH. Although the evidence is minimal for the influence of GST polymorphisms of the alpha, mu, pi, and theta classes on susceptibility to various types of cancer, numerous studies have implicated such genotypic variations in asthma, atherosclerosis, allergies, and other inflammatory diseases. Because diabetes is a disease that involves oxidative damage, and GSH metabolism is dysfunctional in diabetic patients, GSTs may represent a potential target for diabetic drug treatment. In addition, insulin administration is known to result in increased GST gene expression through the PI3K/AKT/mTOR pathway and reduced intracellular oxidative stress, while glucagon decreases such gene expression. Omega-class GST (GSTO) genes, in particular, are associated with neurological diseases such as Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis; again, oxidative stress is believed to be the culprit, with decreased GSTO gene expression resulting in a lowered age of onset for the diseases.
==== MeSH E05.196.401 – electrophoresis ==== MeSH E05.196.401.153 – electrophoresis, agar gel MeSH E05.196.401.153.150 – comet assay MeSH E05.196.401.190 – electrophoresis, capillary MeSH E05.196.401.190.500 – electrophoresis, microchip MeSH E05.196.401.200 – electrophoresis, cellulose acetate MeSH E05.196.401.220 – electrophoresis, gel, pulsed-field MeSH E05.196.401.250 – electrophoresis, gel, two-dimensional MeSH E05.196.401.319 – electrophoresis, paper MeSH E05.196.401.319.670 – nucleotide mapping MeSH E05.196.401.319.670.100 – blotting, northern MeSH E05.196.401.319.670.150 – blotting, southern MeSH E05.196.401.319.720 – peptide mapping MeSH E05.196.401.402 – electrophoresis, polyacrylamide gel MeSH E05.196.401.402.236 – electrophoresis, disc MeSH E05.196.401.402.250 – electrophoresis, gel, two-dimensional MeSH E05.196.401.485 – electrophoresis, starch gel MeSH E05.196.401.500 – electrophoretic mobility shift assay MeSH E05.196.401.568 – immunoelectrophoresis MeSH E05.196.401.568.250 – counterimmunoelectrophoresis MeSH E05.196.401.568.520 – immunoelectrophoresis, two-dimensional MeSH E05.196.401.663 – isoelectric focusing
As larger doses of these pharmaceuticals are administered the plasma concentrations of the unmetabolized drug increases and the elimination half-life increases. It is therefore necessary to adjust the dose or other treatment parameters when a high dosage is required. The kidneys can also establish active elimination mechanisms for some drugs, independent of plasma concentrations. It can therefore be seen that non-linearity can occur because of reasons that affect the entire pharmacokinetic sequence: absorption, distribution, metabolism and elimination.
Sources: en.wikipedia.org
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.
No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.
Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.